Adagene Inc. (ADAG)
Automate Your Wheel Strategy on ADAG
With Tiblio's Option Bot, you can configure your own wheel strategy including ADAG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADAG
- Rev/Share 0.0113
- Book/Share 1.122
- PB 1.3939
- Debt/Equity 0.366
- CurrentRatio 2.2988
- ROIC -0.7936
- MktCap 73679344.0
- FreeCF/Share -0.809
- PFCF -2.0226
- PE -1.4271
- Debt/Assets 0.2072
- DivYield 0
- ROE -0.8426
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ADAG | Morgan Stanley | Overweight | Equal Weight | -- | -- | Jan. 31, 2025 |
News
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with
Read More
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. “Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells.
Read More
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses
Read More
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced an investigator initiated (IIT) Phase 2 neoadjuvant trial of ADG126 for patients with stage II or stage III colorectal cancer. The new study (NCT06846268), led by primary investigator Dr. Yong Wei Peng, Senior Consultant at the Department of Haematology-Oncology, National University Cancer Institute, Singapore, is expected to …
Read More
About Adagene Inc. (ADAG)
- IPO Date 2021-02-09
- Website https://www.adagene.com
- Industry Biotechnology
- CEO Dr. Peter P. Luo Ph.D.
- Employees 138